Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
Neutral primary outcome does not support broad use; extends evidence of consistent effects across eGFR subgroups.
Neuen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: